Avacopan is possibly associated with the improvement of ANCA-associated vasculitis activity without decreasing ANCA titres: a four-case series

Abe, Yoshiyuki; Minowa, Kentaro; Kogami, Masahiro; Ando, Taiki; Makiyama, Ayako; Yamaji, Katsuhiko; Tamura, Naoto

doi:10.1093/rheumatology/kead191

Cited by 4 publications

(1 citation statement)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The study by Merkel et al (2020) suggested that the addition of avacopan to the standard regimen of glucocorticoids combined with RTX or CYC was not only well tolerated, but also shortened the duration of remission at higher doses. Abe et al (2023) reported four cases in which an interesting finding was observed; avacopan did not decrease ANCA titers while reducing AAV activity. van Leeuwen et al (2022) reported that an 84-year-old patient with refractory AAV, who was successful treated avacopan, exhibited a progressive decrease in C3 levels.…”

Section: Biologicsmentioning

confidence: 95%

Application of biological agents in the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis

Liu,

Tian,

Chen

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) has been traditionally treated using glucocorticoids and immunosuppressants. However, these treatment modes are associated with high recurrence AAV rates and adverse reactions. Therefore, treatment strategies for AAV need to be urgently optimized. The efficacy and safety of biological agents in the treatment of vasculitis have been clinically validated. This review comprehensively summarizes the evidence-based support for the clinical use of existing biological agents in AAV. The findings reveal that multiple biological agents not only effectively reduce the adverse reactions associated with glucocorticoids and immunosuppressants but also demonstrate significant therapeutic efficacy. Notably, rituximab, an anti-CD20 antibody, has emerged as a first-line treatment option for AAV. Mepolizumab has shown promising results in relapsed and refractory eosinophilic granulomatosis with polyangiitis. Other biological agents targeting cytokines, complement, and other pathways have also demonstrated clinical benefits in recent studies. The widespread application of biological agents provides new insights into the treatment of AAV and is expected to drive further clinical research. These advancements not only improve patient outcomes but also offer more possibilities and hope in the field of AAV treatment.

show abstract

Section: Biologicsmentioning

confidence: 95%